growth - The 23.5% revenue growth, 129.5% net income growth, and 106% EPS growth attract growth investors seeking high-margin specialty…
Rising rates create modest headwinds through higher discount rates applied to future cash flows…
Watch on earnings: Quarterly Firdapse prescription volume (TRx) from IQVIA or Symphony Health data, Net revenue per patient per year (pricing power indicator), Total diagnosed LEMS patient pool penetration rate (market saturation metric).
One Sentence Summary:
Catalyst Pharmaceuticals: the story is balanced — firdapse patient enrollment numbers and quarterly prescription volume trends.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.